• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

作为非小细胞肺癌中具有**某种突变**的克唑替尼耐药的一种获得性潜在机制的**该突变**。 备注：原文中两个mutation指代不明，我按照字面进行了翻译，翻译出来的句子读起来不通顺，建议你检查下原文是否准确完整。

Mutation of as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with Mutation.

作者信息

Zhu Jinlian, Chen Jie, Liu Wei, Zhang Junling, Gu Yulan

机构信息

Department of Oncology, Affiliated Changshu Hospital of Nantong University, Changshu, Jiangsu Province, People's Republic of China.

Medical Department, 3D Medicines Inc, Shanghai, People's Republic of China.

出版信息

Lung Cancer (Auckl). 2024 Aug 27;15:123-128. doi: 10.2147/LCTT.S467584. eCollection 2024.

DOI:10.2147/LCTT.S467584
PMID:39221108
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11365520/
Abstract

Mesenchymal-epithelial transition () gene has been identified as a promising target for treatments. However, different sites of the mutation show different effects to MET inhibition. Here, we reported a non-small cell lung cancer (NSCLC) patient harboring mutation who achieved a durable partial response to crizotinib with a PFS of 22.4 months. Furthermore, we report for the first time the identification of as a possible mechanism of acquired resistance to crizotinib in a patient with mutation during disease progression.

摘要

间充质-上皮转化（）基因已被确定为一种有前景的治疗靶点。然而，该突变的不同位点对MET抑制表现出不同的效果。在此，我们报告了一名携带该突变的非小细胞肺癌（NSCLC）患者，其对克唑替尼取得了持久的部分缓解，无进展生存期为22.4个月。此外，我们首次报告了在一名携带该突变的患者疾病进展过程中，发现该情况是对克唑替尼获得性耐药的一种可能机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3100/11365520/befb49a531a8/LCTT-15-123-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3100/11365520/9269f5893244/LCTT-15-123-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3100/11365520/befb49a531a8/LCTT-15-123-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3100/11365520/9269f5893244/LCTT-15-123-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3100/11365520/befb49a531a8/LCTT-15-123-g0002.jpg

相似文献

1
Mutation of as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with Mutation.作为非小细胞肺癌中具有**某种突变**的克唑替尼耐药的一种获得性潜在机制的**该突变**。 备注：原文中两个mutation指代不明，我按照字面进行了翻译，翻译出来的句子读起来不通顺，建议你检查下原文是否准确完整。
Lung Cancer (Auckl). 2024 Aug 27;15:123-128. doi: 10.2147/LCTT.S467584. eCollection 2024.
2
A rapid and durable response to cabozantinib in an osimertinib-resistant lung cancer patient with D1228N mutation: a case report.一例携带D1228N突变的奥希替尼耐药肺癌患者对卡博替尼产生快速且持久反应：病例报告
Ann Transl Med. 2021 Aug;9(16):1354. doi: 10.21037/atm-21-3861.
3
Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.获得性 MET D1228N 突变介导 ROS1 融合肺腺癌对克唑替尼的耐药：一例报告。
Oncologist. 2021 Mar;26(3):178-181. doi: 10.1002/onco.13545. Epub 2020 Oct 28.
4
Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.携带有间充质-上皮转化因子外显子 14 跳跃突变的肺腺癌患者对克唑替尼和卡博替尼的反应：一例报告。
Medicine (Baltimore). 2021 Jan 29;100(4):e24300. doi: 10.1097/MD.0000000000024300.
5
Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.病例报告：MET 外显子 14 跳跃的 NSCLC 中曲妥珠单抗耐药的机制为 HER2 扩增。
Cancer Biol Ther. 2019;20(6):837-842. doi: 10.1080/15384047.2019.1566049. Epub 2019 Feb 11.
6
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.克唑替尼联合或不联合 EGFR-TKI 治疗 EGFR 突变型 NSCLC 患者 EGFR-TKI 治疗失败后获得性 MET 扩增：一项多中心回顾性研究。
J Transl Med. 2019 Feb 21;17(1):52. doi: 10.1186/s12967-019-1803-9.
7
Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.克唑替尼治疗 MET 外显子 14 突变或 MET 扩增的晚期非小细胞肺癌：一项回顾性、单机构经验。
Oncology. 2022;100(9):467-474. doi: 10.1159/000525188. Epub 2022 Jun 9.
8
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.基于 DNA 的高度精确检测和治疗肺癌中 MET 外显子 14 跳跃突变的结果。
Lung Cancer. 2020 Feb;140:46-54. doi: 10.1016/j.lungcan.2019.11.010. Epub 2019 Nov 18.
9
Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and fusion.病例报告：一名非小细胞肺癌伴融合患者因MET Y1230H突变获得对克唑替尼的耐药性。
Front Oncol. 2024 Apr 16;14:1370901. doi: 10.3389/fonc.2024.1370901. eCollection 2024.
10
Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.阿法替尼和克唑替尼治疗后晚期非小细胞肺癌患者出现 EGFR L861Q 突变和获得性 MET 扩增的持久完全缓解：病例报告。
Ann Palliat Med. 2020 Sep;9(5):3609-3613. doi: 10.21037/apm-19-482. Epub 2020 Jun 29.

本文引用的文献

1
Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer.初治MET融合阳性晚期非小细胞肺癌对MET抑制剂的反应及获得性耐药
Lung Cancer. 2023 Apr;178:66-74. doi: 10.1016/j.lungcan.2023.01.017. Epub 2023 Feb 1.
2
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.非小细胞肺癌中 MET 酪氨酸激酶结构域的突变与酪氨酸激酶抑制剂耐药性。
Respir Res. 2023 Jan 25;24(1):28. doi: 10.1186/s12931-023-02329-1.
3
MET alterations in NSCLC-Current Perspectives and Future Challenges.
非小细胞肺癌中的 MET 改变：现状与未来挑战。
J Thorac Oncol. 2023 Apr;18(4):419-435. doi: 10.1016/j.jtho.2022.10.015. Epub 2022 Oct 29.
4
Functional Analysis of MET Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination.MET 外显子 14 跳跃改变在癌症侵袭和转移扩散中的功能分析。
Cancer Res. 2022 Apr 1;82(7):1365-1379. doi: 10.1158/0008-5472.CAN-21-1327.
5
Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.在具有MET外显子14跳跃突变的非小细胞肺癌中，卡博替尼克服克唑替尼对获得性耐药突变MET D1228N的耐药性。
JCO Precis Oncol. 2021 Nov;5:849-853. doi: 10.1200/PO.21.00076.
6
MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping.MET D1228N 和 D1246N 是 MET 外显子 14 跳跃中的相同耐药突变。
Oncologist. 2021 Dec;26(12):e2297-e2301. doi: 10.1002/onco.13924. Epub 2021 Aug 17.
7
Genomic and clinical characteristics of exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib.一大群中国癌症患者中14号外显子改变的基因组和临床特征揭示了独特的特征以及克唑替尼的一种新耐药机制。
J Cancer. 2021 Jan 1;12(3):644-651. doi: 10.7150/jca.49391. eCollection 2021.
8
Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.获得性 MET D1228N 突变介导 ROS1 融合肺腺癌对克唑替尼的耐药：一例报告。
Oncologist. 2021 Mar;26(3):178-181. doi: 10.1002/onco.13545. Epub 2020 Oct 28.
9
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers.中国肺癌中MET外显子14改变的特征及其与克唑替尼临床疗效的关联
Lung Cancer. 2020 Oct;148:113-121. doi: 10.1016/j.lungcan.2020.08.009. Epub 2020 Aug 19.
10
Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.克唑替尼治疗期间 MET 扩增三阴性乳腺癌进展时获得对卡博替尼敏感的 MET D1228N 突变。
Clin Breast Cancer. 2020 Aug;20(4):e433-e438. doi: 10.1016/j.clbc.2020.02.003. Epub 2020 Feb 19.